uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerGlobeNewsWire • 06/11/25
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairGlobeNewsWire • 05/19/25
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?Zacks Investment Research • 05/14/25
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressGlobeNewsWire • 05/09/25
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's DataSeeking Alpha • 05/08/25
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130Seeking Alpha • 04/21/25
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 04/17/25
uniQure Announces 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/27/25
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval BeckonsSeeking Alpha • 02/20/25
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsBenzinga • 02/07/25
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BPRNewsWire • 02/07/25
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseGlobeNewsWire • 02/03/25
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSGlobeNewsWire • 01/30/25